BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012;141:20-6. [PMID: 21940766 DOI: 10.1378/chest.11-0404] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Strange G, Lau EM, Giannoulatou E, Corrigan C, Kotlyar E, Kermeen F, Williams T, Celermajer DS, Dwyer N, Whitford H, Wrobel JP, Feenstra J, Lavender M, Whyte K, Collins N, Steele P, Proudman S, Thakkar V, Keating D, Keogh A. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart, Lung and Circulation 2018;27:1368-75. [DOI: 10.1016/j.hlc.2017.08.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
2 Ho L, Hossen N, Nguyen T, Vo A, Ahsan F. Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension. Biomedicines 2022;10:170. [DOI: 10.3390/biomedicines10010170] [Reference Citation Analysis]
3 DuBrock HM, Cartin-Ceba R, Channick RN, Kawut SM, Krowka MJ. Sex Differences in Portopulmonary Hypertension. Chest 2021;159:328-36. [PMID: 32798521 DOI: 10.1016/j.chest.2020.07.081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Frump AL, Goss KN, Vayl A, Albrecht M, Fisher A, Tursunova R, Fierst J, Whitson J, Cucci AR, Brown MB, Lahm T. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol 2015;308:L873-90. [PMID: 25713318 DOI: 10.1152/ajplung.00006.2015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 11.3] [Reference Citation Analysis]
5 Austin ED, Loyd JE. Toward Precision Medicine in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015;192:1272-4. [PMID: 26623685 DOI: 10.1164/rccm.201508-1607ED] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ventetuolo CE, Lima JA, Barr RG, Bristow MR, Bagiella E, Chahal H, Kizer JR, Lederer DJ, Bluemke DA, Kawut SM. The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study. Pulm Circ 2012;2:379-86. [PMID: 23130107 DOI: 10.4103/2045-8932.101657] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
7 Karnes JH, Wiener HW, Schwantes-An TH, Natarajan B, Sweatt AJ, Chaturvedi A, Arora A, Batai K, Nair V, Steiner HE, Giles JB, Yu J, Hosseini M, Pauciulo MW, Lutz KA, Coleman AW, Feldman J, Vanderpool R, Tang H, Garcia JGN, Yuan JX, Kittles R, de Jesus Perez V, Zamanian RT, Rischard F, Tiwari HK, Nichols WC, Benza RL, Desai AA. Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2020;201:1407-15. [PMID: 31916850 DOI: 10.1164/rccm.201907-1447OC] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Al-Naamani N, Ventetuolo CE. Another Piece in the Estrogen Puzzle of Pulmonary Hypertension. Am J Respir Crit Care Med 2020;201:274-5. [PMID: 31689368 DOI: 10.1164/rccm.201910-1982ED] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171:580-594. [PMID: 23981051 DOI: 10.1111/bph.12362] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
10 Wallace E, Morrell NW, Yang XD, Long L, Stevens H, Nilsen M, Loughlin L, Mair KM, Baker AH, MacLean MR. A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension. Am J Respir Crit Care Med 2015;191:1432-42. [PMID: 25871906 DOI: 10.1164/rccm.201412-2148OC] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
11 van Riel ACMJ, Schuuring MJ, van Hessen ID, van Dijk APJ, Hoendermis ES, Yip JW, Mulder BJM, Bouma BJ. Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome. Neth Heart J 2016;24:410-6. [PMID: 26984567 DOI: 10.1007/s12471-016-0820-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Xanthouli P, Eichstaedt CA, Ewinger M, Marra AM, Grünig E. Pulmonalarterielle Hypertonie bei Frauen. Aktuelle Kardiologie 2022;11:30-4. [DOI: 10.1055/a-1692-1006] [Reference Citation Analysis]
13 Hester J, Ventetuolo C, Lahm T. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. Compr Physiol 2019;10:125-70. [PMID: 31853950 DOI: 10.1002/cphy.c190011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
14 Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, Duffy J, Gaston B, Heller NM, Hemnes A, Henske EP, Jain R, Lahm T, Lancaster LH, Lee J, Legato MJ, McKee S, Mehra R, Morris A, Prakash YS, Stampfli MR, Gopal-Srivastava R, Laposky AD, Punturieri A, Reineck L, Tigno X, Clayton J. Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. Am J Respir Crit Care Med 2018;198:850-8. [PMID: 29746147 DOI: 10.1164/rccm.201801-0168WS] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
15 Mauvais-Jarvis F, Berthold HK, Campesi I, Carrero JJ, Dakal S, Franconi F, Gouni-Berthold I, Heiman ML, Kautzky-Willer A, Klein SL, Murphy A, Regitz-Zagrosek V, Reue K, Rubin JB. Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacol Rev 2021;73:730-62. [PMID: 33653873 DOI: 10.1124/pharmrev.120.000206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
16 Jacobs W, van de Veerdonk MC, Trip P, de Man F, Heymans MW, Marcus JT, Kawut SM, Bogaard HJ, Boonstra A, Vonk Noordegraaf A. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest 2014;145:1230-6. [PMID: 24306900 DOI: 10.1378/chest.13-1291] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 13.8] [Reference Citation Analysis]
17 Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J 2014;43:523-30. [PMID: 23949961 DOI: 10.1183/09031936.00027613] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
18 Marra AM, Benjamin N, Eichstaedt C, Salzano A, Arcopinto M, Gargani L, D Alto M, Argiento P, Falsetti L, Di Giosia P, Isidori AM, Ferrara F, Bossone E, Cittadini A, Grünig E. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacol Res 2016;114:103-9. [PMID: 27771466 DOI: 10.1016/j.phrs.2016.10.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
19 Lythgoe MP, Rhodes CJ, Ghataorhe P, Attard M, Wharton J, Wilkins MR. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacology & Therapeutics 2016;164:195-203. [DOI: 10.1016/j.pharmthera.2016.04.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
20 Leopold JA, Kawut SM, Aldred MA, Archer SL, Benza RL, Bristow MR, Brittain EL, Chesler N, DeMan FS, Erzurum SC, Gladwin MT, Hassoun PM, Hemnes AR, Lahm T, Lima JAC, Loscalzo J, Maron BA, Rosa LM, Newman JH, Redline S, Rich S, Rischard F, Sugeng L, Tang WHW, Tedford RJ, Tsai EJ, Ventetuolo CE, Zhou Y, Aggarwal NR, Xiao L. Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circ Heart Fail 2021;14:e007975. [PMID: 34422205 DOI: 10.1161/CIRCHEARTFAILURE.120.007975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rhee RL, Gabler NB, Praestgaard A, Merkel PA, Kawut SM. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol 2015;67:2457-65. [PMID: 26016953 DOI: 10.1002/art.39220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lachant DJ, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ. Combination therapy improves vascular volume in female rats with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2019;317:L445-55. [PMID: 31322432 DOI: 10.1152/ajplung.00450.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2014;307:L7-26. [PMID: 24816487 DOI: 10.1152/ajplung.00337.2013] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 10.9] [Reference Citation Analysis]
24 Foderaro A, Ventetuolo CE. Pulmonary Arterial Hypertension and the Sex Hormone Paradox. Curr Hypertens Rep 2016;18:84. [PMID: 27832457 DOI: 10.1007/s11906-016-0689-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
25 Ventetuolo CE, Mitra N, Wan F, Manichaikul A, Barr RG, Johnson C, Bluemke DA, Lima JA, Tandri H, Ouyang P, Kawut SM. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J 2016;47:553-63. [PMID: 26647441 DOI: 10.1183/13993003.01083-2015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
26 Rodriguez-Arias JJ, García-Álvarez A. Sex Differences in Pulmonary Hypertension. Front Aging 2021;2:727558. [PMID: 35822006 DOI: 10.3389/fragi.2021.727558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Groban L, Lindsey SH, Wang H, Alencar AK. Sex and Gender Differences in Cardiovascular Disease. Sex Differences in Physiology. Elsevier; 2016. pp. 61-87. [DOI: 10.1016/b978-0-12-802388-4.00005-7] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Goncharova EA, Gladwin MT, Kawut SM. Update in Pulmonary Vascular Diseases 2014. Am J Respir Crit Care Med 2015;192:544-50. [PMID: 26561677 DOI: 10.1164/rccm.201504-0829up] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Karnati SA, Wee A, Shirke MM, Harky A. Racial disparities and cardiovascular disease: One size fits all approach? J Card Surg 2020;35:3530-8. [PMID: 32949061 DOI: 10.1111/jocs.15047] [Reference Citation Analysis]
30 Judge EP, Gaine SP. Management of pulmonary arterial hypertension: . Current Opinion in Critical Care 2013;19:44-50. [DOI: 10.1097/mcc.0b013e32835c5137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Hatton N, Ryan JJ. Sex differences in response to pulmonary arterial hypertension therapy: is what's good for the goose, good for the gander? Chest 2014;145:1184-6. [PMID: 24889427 DOI: 10.1378/chest.13-3061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
32 Austin ED, Hamid R. Deconstructing the Melting Pot in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2020;201:1329-31. [PMID: 32053755 DOI: 10.1164/rccm.202001-0156ED] [Reference Citation Analysis]
33 Ventetuolo CE, Klinger JR. WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Prog Cardiovasc Dis 2012;55:89-103. [PMID: 23009906 DOI: 10.1016/j.pcad.2012.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
34 Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz H, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth H, Held M, Dumitrescu D, Tsangaris I, Vonk-noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt K, Rosenkranz S, Lange TJ. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.03.011] [Reference Citation Analysis]
35 Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015;192:1345-54. [PMID: 26252367 DOI: 10.1164/rccm.201501-0196OC] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
36 Ong MS, Abman S, Austin ED, Feinstein JA, Hopper RK, Krishnan US, Mullen MP, Natter MD, Raj JU, Rosenzweig EB, Mandl KD; Pediatric Pulmonary Hypertension Network and National Heart, Lung, and Blood Institute Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center Investigators. Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry. J Pediatr 2019;211:63-71.e6. [PMID: 31176455 DOI: 10.1016/j.jpeds.2019.04.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
37 Umar S, Rabinovitch M, Eghbali M. Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am J Respir Crit Care Med 2012;186:125-31. [PMID: 22561960 DOI: 10.1164/rccm.201201-0058PP] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
38 Hye T, Dwivedi P, Li W, Lahm T, Nozik-Grayck E, Stenmark KR, Ahsan F. Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2021;320:L1025-37. [PMID: 33719549 DOI: 10.1152/ajplung.00559.2020] [Reference Citation Analysis]
39 Ahn LY, Kim SE, Yi S, Dingemanse J, Lim KS, Jang IJ, Yu KS. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. Am J Cardiovasc Drugs 2014;14:377-85. [PMID: 24906252 DOI: 10.1007/s40256-014-0081-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
40 Docherty CK, Harvey KY, Mair KM, Griffin S, Denver N, MacLean MR. The Role of Sex in the Pathophysiology of Pulmonary Hypertension. Adv Exp Med Biol 2018;1065:511-28. [PMID: 30051404 DOI: 10.1007/978-3-319-77932-4_31] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
41 Badlam JB, Austin ED. Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension. Eur Respir J 2018;51:1801058. [PMID: 29954927 DOI: 10.1183/13993003.01058-2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lahm T, Frump AL, Albrecht ME, Fisher AJ, Cook TG, Jones TJ, Yakubov B, Whitson J, Fuchs RK, Liu A, Chesler NC, Brown MB. 17β-Estradiol mediates superior adaptation of right ventricular function to acute strenuous exercise in female rats with severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2016;311:L375-88. [PMID: 27288487 DOI: 10.1152/ajplung.00132.2016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
43 Martin YN, Pabelick CM. Sex differences in the pulmonary circulation: implications for pulmonary hypertension. Am J Physiol Heart Circ Physiol 2014;306:H1253-64. [PMID: 24610923 DOI: 10.1152/ajpheart.00857.2013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
44 Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA. Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS One 2017;12:e0187734. [PMID: 29121097 DOI: 10.1371/journal.pone.0187734] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
45 Goel K, Hon SM, Farber HW, George MP. Pulmonary Arterial Hypertension: What Rare Diseases Tell Us About Disparities in Disease Registries, Clinical Trials, and Treatment Algorithms. Chest 2021;160:1981-3. [PMID: 34743846 DOI: 10.1016/j.chest.2021.06.010] [Reference Citation Analysis]
46 Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med 2017;195:1661-70. [PMID: 28430547 DOI: 10.1164/rccm.201701-0150WS] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 8.4] [Reference Citation Analysis]
47 Baird GL, Archer-Chicko C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P, Palevsky HI, Palmisicano AJ, Pinder D, Preston IR, Roberts KE, Smith KA, Walsh T, Whittenhall M, Ventetuolo CE. Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. Eur Respir J 2018;51:1800467. [PMID: 29954925 DOI: 10.1183/13993003.00467-2018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
48 Yang BQ, Assad TR, O'Leary JM, Xu M, Halliday SJ, D'Amico RW, Farber-Eger EH, Wells QS, Hemnes AR, Brittain EL. Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. Pulm Circ 2018;8:2045894018764273. [PMID: 29480090 DOI: 10.1177/2045894018764273] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
49 Walsh TP, Baird GL, Atalay MK, Agarwal S, Arcuri D, Klinger JR, Mullin CJ, Morreo H, Normandin B, Shiva S, Whittenhall M, Ventetuolo CE. Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial. Pulm Circ 2021;11:2045894021989554. [PMID: 34094503 DOI: 10.1177/2045894021989554] [Reference Citation Analysis]
50 Suzuki M, Ogawa K. Clinical studies on digoxin intoxication II. Relationship between plasma and erythrocyte digoxin concentrations. Jpn Heart J 1980;21:497-504. [PMID: 7420733 DOI: 10.1536/ihj.21.497] [Reference Citation Analysis]
51 Al-Naamani N, Paulus JK, Roberts KE, Pauciulo MW, Lutz K, Nichols WC, Kawut SM. Racial and ethnic differences in pulmonary arterial hypertension. Pulm Circ 2017;7:793-6. [PMID: 28849992 DOI: 10.1177/2045893217732213] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
52 Gohar EY, Pollock DM. Sex-Specific Contributions of Endothelin to Hypertension. Curr Hypertens Rep 2018;20:58. [PMID: 29884912 DOI: 10.1007/s11906-018-0856-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
53 Halliday SJ, Hemnes AR. Identifying "super responders" in pulmonary arterial hypertension. Pulm Circ 2017;7:300-11. [PMID: 28597766 DOI: 10.1177/2045893217697708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
54 Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013;143:315-23. [PMID: 22814814 DOI: 10.1378/chest.12-0270] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
55 Kjellström B, Nisell M, Kylhammar D, Bartfay SE, Ivarsson B, Rådegran G, Hjalmarsson C. Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016. ERJ Open Res 2019;5:00075-2019. [PMID: 31423450 DOI: 10.1183/23120541.00075-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Mayfield JJ, Papolos A, Vasti E, De Marco T, Tison GH. Pulmonary arterial capacitance predicts outcomes in patients with pulmonary hypertension independent of race/ethnicity, sex, and etiology. Respir Med 2020;163:105891. [PMID: 32056840 DOI: 10.1016/j.rmed.2020.105891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Gillis EE, Sasser JM, Sullivan JC. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females. Am J Physiol Regul Integr Comp Physiol 2016;310:R691-6. [PMID: 26936781 DOI: 10.1152/ajpregu.00427.2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wright LM, Dwyer N, Celermajer D, Kritharides L, Marwick TH. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging 2016;9:733-46. [PMID: 27282440 DOI: 10.1016/j.jcmg.2016.02.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
59 Otero R, Elías T, Jara L, Trujillo-Santos J, Bertoletti L, Nauffal D, Ruiz-Ruiz J, Blanco-Molina Á, Monreal M; RIETE investigators. Factors associated with elevated pulmonary arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism. Thromb Res 2013;131:e191-5. [PMID: 23466216 DOI: 10.1016/j.thromres.2013.01.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
60 Franco V, Ryan JJ, McLaughlin VV. Pulmonary Hypertension in Women. Heart Fail Clin 2019;15:137-45. [PMID: 30449376 DOI: 10.1016/j.hfc.2018.08.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Petitto M, Esposito R, Sorrentino R, Lembo M, Luciano F, De Roberto AM, La Mura L, Pezzullo E, Maffei S, Galderisi M, Lancellotti P. Sex-specific echocardiographic reference values: the women's point of view. J Cardiovasc Med (Hagerstown) 2018;19:527-35. [PMID: 30015781 DOI: 10.2459/JCM.0000000000000696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Duarte JD, Hanson RL, Machado RF. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol 2013;9:335-49. [PMID: 23668740 DOI: 10.2217/fca.13.6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
63 Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56. [PMID: 22696079 DOI: 10.1161/CIRCULATIONAHA.112.105890] [Cited by in Crossref: 152] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
64 Diaz R, Ferrer G. Pulmonary Arterial Hypertension in Hispanics. Cureus 2019;11:e5834. [PMID: 31754569 DOI: 10.7759/cureus.5834] [Reference Citation Analysis]
65 Sardanelli F, Alì M, Hunink MG, Houssami N, Sconfienza LM, Di Leo G. To share or not to share? Expected pros and cons of data sharing in radiological research. Eur Radiol 2018;28:2328-35. [PMID: 29349697 DOI: 10.1007/s00330-017-5165-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
66 Al-Hilal TA, Keshavarz A, Kadry H, Lahooti B, Al-Obaida A, Ding Z, Li W, Kamm R, McMurtry IF, Lahm T, Nozik-Grayck E, Stenmark KR, Ahsan F. Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application. Lab Chip 2020;20:3334-45. [PMID: 32749432 DOI: 10.1039/d0lc00605j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Smoliga JM, Colombo ES, Campen MJ. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age‐related diseases in healthy populations. Aging (Albany NY) 2013;5:495-506. [PMID: 24073437 DOI: 10.18632/aging.100579] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
68 Kim IG, So WY, Sung DJ. The relationships between lifestyle factors and hypertension in community-dwelling Korean adults. J Phys Ther Sci 2015;27:3689-92. [PMID: 26834333 DOI: 10.1589/jpts.27.3689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
69 Rich S. The importance of sex in pulmonary hypertension. Chest 2012;141:4-5. [PMID: 22215821 DOI: 10.1378/chest.11-2225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest 2015;147:188-97. [PMID: 25122150 DOI: 10.1378/chest.14-0263] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
71 Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Shimizu T, Nochioka K, Sato H, Konno R, Satoh K, Miyata S, Shimokawa H. Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. Heart Vessels 2018;33:939-47. [PMID: 29441403 DOI: 10.1007/s00380-018-1140-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
72 Rusiecki J, Rao Y, Cleveland J, Rhinehart Z, Champion HC, Mathier MA. Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. Pulm Circ 2015;5:701-6. [PMID: 26697177 DOI: 10.1086/683829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
73 Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64:583-620. [PMID: 22659328 DOI: 10.1124/pr.111.005587] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
74 Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol 2014;171:567-79. [PMID: 23802760 DOI: 10.1111/bph.12281] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
75 Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC, Jaïs X, Bertoletti L, Sitbon O, Weatherald J, Humbert M, Montani D. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev 2021;30:200330. [PMID: 34750113 DOI: 10.1183/16000617.0330-2020] [Reference Citation Analysis]
76 Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ 2013;3:739-56. [PMID: 25006392 DOI: 10.1086/674770] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 11.0] [Reference Citation Analysis]
77 Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, Phillips Iii JA, Gaddipati R, Gladson S, Gu E, West J, Lane KB. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012;3:6. [PMID: 22348410 DOI: 10.1186/2042-6410-3-6] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
78 Medrek SK, Sahay S. Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. Chest 2018;153:310-20. [PMID: 28887060 DOI: 10.1016/j.chest.2017.08.1159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
79 Coons JC, Crisamore K, Adams S, Modany A, Simon MA, Zhao W, Shaik IH, Venkataramanan R, Empey PE. A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Ther Adv Respir Dis 2021;15:17534666211013688. [PMID: 33929912 DOI: 10.1177/17534666211013688] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Thenappan T, Weir EK. The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension. Am J Cardiol 2017;120:S69-70. [PMID: 29025572 DOI: 10.1016/j.amjcard.2017.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
81 Wang J, Zhang Z, Liang C, Lv T, Yu H, Ren S, Lin P, Du G, Sun L. Targeting Myadm to Intervene Pulmonary Hypertension on Rats Before Pregnancy Alleviates the Effect on Their Offspring's Cardiac-Cerebral Systems. Front Pharmacol 2021;12:791370. [PMID: 35115938 DOI: 10.3389/fphar.2021.791370] [Reference Citation Analysis]
82 Zemskova M, McClain N, Niihori M, Varghese MV, James J, Rafikov R, Rafikova O. Necrosis-Released HMGB1 (High Mobility Group Box 1) in the Progressive Pulmonary Arterial Hypertension Associated With Male Sex. Hypertension 2020;76:1787-99. [PMID: 33012199 DOI: 10.1161/HYPERTENSIONAHA.120.16118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
83 Blanco I, Mathai S, Shafiq M, Boyce D, M Kolb T, Chami H, K Hummers L, Housten T, Chaisson N, L Zaiman A, M Wigley F, J Tedford R, A Kass D, Damico R, E Girgis R, M Hassoun P. Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) 2014;93:177-85. [PMID: 25181310 DOI: 10.1097/MD.0000000000000032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
84 Kwapiszewska G, Johansen AKZ, Gomez-Arroyo J, Voelkel NF. Role of the Aryl Hydrocarbon Receptor/ARNT/Cytochrome P450 System in Pulmonary Vascular Diseases. Circ Res 2019;125:356-66. [PMID: 31242807 DOI: 10.1161/CIRCRESAHA.119.315054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
85 Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, Oka M. Gender, sex hormones and pulmonary hypertension. Pulm Circ 2013;3:294-314. [PMID: 24015330 DOI: 10.4103/2045-8932.114756] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
86 Heresi GA, Love TE, Tonelli AR, Highland KB, Dweik RA. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival. Am J Respir Crit Care Med 2018;198:1090-3. [PMID: 29949380 DOI: 10.1164/rccm.201801-0059LE] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Gohar EY, Yusuf C, Pollock DM. Ovarian hormones modulate endothelin A and B receptor expression. Life Sci 2016;159:148-52. [PMID: 26776836 DOI: 10.1016/j.lfs.2016.01.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
88 Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. J Investig Med 2021;69:1270-80. [PMID: 34580123 DOI: 10.1136/jim-2021-002027] [Reference Citation Analysis]
89 Memon HA, Park MH. Pulmonary Arterial Hypertension in Women. Methodist Debakey Cardiovasc J 2017;13:224-37. [PMID: 29744015 DOI: 10.14797/mdcj-13-4-224] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
90 Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 2012;91:528-39. [PMID: 22967485 DOI: 10.1016/j.lfs.2012.07.034] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
91 Maarman G, Blackhurst D, Thienemann F, Blauwet L, Butrous G, Davies N, Sliwa K, Lecour S. Melatonin as a preventive and curative therapy against pulmonary hypertension. J Pineal Res 2015;59:343-53. [PMID: 26201290 DOI: 10.1111/jpi.12263] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]